Studies on Inflammatory bowel disease and functional gastrointestinal disorders in children and adults

Hoekman, D. R.

Citation for published version (APA): 

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
REFERENCES


40. Ben-Horin S, Yazvori M, Katz L, et al. The immunogenic part of infliximab is the F(ab’)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. *Gut* 2011; 60: 41–8.


109. Lee YJ, Park KS. Irritable bowel syndrome:


---

**REFERENCES** 281


238. Candy DCA, Edwards D, Geraint M. Treatment of faecal impaction with polyethylene glycol plus electrolytes (PEG + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy. J Pediatr Gastroenterol Nutr...


constipation. Cochrane Database Syst Rev 2010; CD007570.


Corinllie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and...
decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; gutjnrl.2012-304094.


499. Willot S, Vermeire S, Ohresen M, et al. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in
500. Lasson A, Stotzer P-O, Öhman L, et al. The intra-
individual variability of faecal calprotectin: a
prospective study in patients with active ulcerative

prospective single-centre evaluation of the intra-
individual variability of faecal calprotectin in
quiescent Crohn's disease. Aliment Pharmacol Ther

calprotectin is equally sensitive in Crohn's disease
affecting the small bowel and colon. Scand J

disease location on faecal calprotectin levels in
Crohn's disease. Scand J Gastroenterol 2015; 50:
841–7.

evidence based consensus for endoscopy in
inflammatory bowel disease. J Crohns Colitis 2013;
7: 982–1038.

Relationship of clinical symptoms with biomarkers of
inflammation in pediatric inflammatory bowel

506. Afzal NA, van der Zaag-Loonen HJ, Arnaud-
Battandier F, et al. Improvement in quality of life
of children with acute Crohn's disease does not
parallel mucosal healing after treatment with
exclusive enteral nutrition. Aliment Pharmacol Ther

Healing for Paediatric Crohn's Disease: Is It Really
Worth the Effort or Just Much Ado About Nothing?

crohn's disease: two separate disease entities?

Cheilitis granulomatosa. J Eur Acad Dermatology

510. Grave B, McCullough M, Wiesenfeld D. Orofacial
granulomatosis—a 20-year review. Oral Dis 2009;
15: 46–51.

511. Lauzerrini M, Bramuzzo M, Ventura A. Association
between orofacial granulomatosis and Crohn's
disease in children: systematic review. World J
Gastroenterol 2014; 20: 7497–504.

cavity in Crohn's disease. J Pediatr 2001; 138:
767–71.

513. Sanderson J, Nunes C, Escudier M, et al. Oro-
facial granulomatosis: Crohn's disease or a new
inflammatory bowel disease? Inflamm Bowel Dis

514. Simonsen AB, Deleuran M. Orofacial
Granulomatosis in Children can be the Initial
Manifestation of Systemic Disease: A Presentation
of Two Cases. Dermatology reports 2014; 6: 5039.

515. Tilakaratne WM, Freysdottir J, Fortune F. Orofacial
granulomatosis: review on aetiology and

516. O'Neil ID, Scully C. Biologics in oral medicine: oral
Crohn's disease and orofacial granulomatosis. Oral

outcome for children who present with oral
manifestations of Crohn's disease. Eur Arch Paediatr

518. Al Johani KA, Moles DR, Hodgson TA, et al.
Orofacial granulomatosis: clinical features and
long-term outcome of therapy. J Am Acad Dermatol

519. Quigley EMM. Overlapping irritable bowel
syndrome and inflammatory bowel disease: less to
than meets the eye? Therap Adv Gastroenterol
2015; 9: 1756283X15621230.

520. Zimmerman LA, Srinath AI, Goyal A, et al. The
overlap of functional abdominal pain in pediatric
Crohn's disease. Inflamm Bowel Dis 2013; 19:
826–31.

IBS-like symptoms in patients with inflammatory
bowel disease in remission; relationships with
quality of life and coping behavior. Dig Dis Sci

522. Zubin G, Peter L. Predicting Endoscopic Crohn's
Disease Activity Before and After Induction
Therapy in Children: A Comprehensive Assessment
of PCDAI, CRP, and Fecal Calprotectin. Inflamm

523. Click B, Vargas EJ, Anderson AM, et al. Silent
Crohn's Disease. Inflamm Bowel Dis 2015; 21:
2254–61.

524. Nederlandse Vereniging voor Kindergeneeskunde.
Richtlijn Diagnostiek en behandeling van
inflammatoire darmziekten bij kinderen.
Richtlijn Diagnostiek en behandeling van
inflammatoire darmziekten bij kinderen. Van
Zuiden Communications BV, 2008.

525. El-Matary W, Spray C, Sandhu B. Irritable bowel
syndrome: the commonest cause of recurrent
163: 584–8.

526. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H,
et al. Functional bowel symptoms in quiescent
inflammatory bowel diseases: role of epithelial
barrier disruption and low-grade inflammation.

TRPV1 receptor differs in quiescent inflammatory


